BOSTON — Greet­ings from Boston, where I’ve been on the ground cov­er­ing the Amer­i­can So­ci­ety of Gene & Cell Ther­a­py’s an­nu­al meet­ing all week.

It’s...

Land­ing a re­duced 20% tar­iff rate will re­quire phar­ma com­pa­nies to fill out ex­ten­sive pa­per­work and be close­ly mon­i­tored by the De­part­ment of Com­merce.

Pres­i­dent...

A gene ther­a­py de­signed by En­cod­ed Ther­a­peu­tics re­duced seizures by 76% in chil­dren with Dravet syn­drome, a se­vere neu­rode­vel­op­men­tal dis­or­der.

The re­mark­able re­duc­tion was ob­served on­ly...

Here we go again?

Bio­gen re­port­ed heav­i­ly an­tic­i­pat­ed Alzheimer’s da­ta, say­ing its tau-tar­get­ing drug BI­IB080 missed its pri­ma­ry end­point in a Phase 2 study but...

A com­bi­na­tion of As­traZeneca's Imfinzi with Pfiz­er and Astel­las’ Pad­cev kept more blad­der can­cer pa­tients alive than stan­dard of care, the com­pa­ny said Thurs­day.

As­traZeneca...